We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Palatin Technologies (PTN) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Palatin Technologies (PTN - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of PTN and the rest of the Medical group's stocks.
Palatin Technologies is a member of the Medical sector. This group includes 870 individual stocks and currently holds a Zacks Sector Rank of #1. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. PTN is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for PTN's full-year earnings has moved 68.75% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, PTN has returned 45.40% so far this year. Meanwhile, stocks in the Medical group have gained about 4.42% on average. This means that Palatin Technologies is outperforming the sector as a whole this year.
Looking more specifically, PTN belongs to the Medical - Biomedical and Genetics industry, which includes 368 individual stocks and currently sits at #57 in the Zacks Industry Rank. This group has gained an average of 0.79% so far this year, so PTN is performing better in this area.
PTN will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Palatin Technologies (PTN) Outperforming Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of Palatin Technologies (PTN - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of PTN and the rest of the Medical group's stocks.
Palatin Technologies is a member of the Medical sector. This group includes 870 individual stocks and currently holds a Zacks Sector Rank of #1. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. PTN is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for PTN's full-year earnings has moved 68.75% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, PTN has returned 45.40% so far this year. Meanwhile, stocks in the Medical group have gained about 4.42% on average. This means that Palatin Technologies is outperforming the sector as a whole this year.
Looking more specifically, PTN belongs to the Medical - Biomedical and Genetics industry, which includes 368 individual stocks and currently sits at #57 in the Zacks Industry Rank. This group has gained an average of 0.79% so far this year, so PTN is performing better in this area.
PTN will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.